Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 128.21 B
The data is delayed by 15 minutes.
Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company?s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||1.67 B||EPS||2.51||EPS Growth - 4 Quarters||-704.03%||EPS Growth - Q/Q||-233.04%|
|EPS Growth - Y/Y||-255.12%||Sales Growth - 4 Quarters||6.17%||Sales Growth - Q/Q||3.02%||P/E||21.7|
|P/E To EPS Growth||0.28||P/S||7.83||P/BV||8.48||Price/Cash Per Share||23.41|
|Price/Free Cash Flow||48.9||ROA||5.6%||ROE||11.84%||ROI||7.56%|
|Current Ratio||1.76||Quick Ratio||1.58||Long Term Debt/Equity||1.18||Debt Ratio||0.49|
|Gross Margin||76.6%||Operating Margin||14.94%||Net Profit Margin||10.93%||Dividend Payout Ratio||-136.15%|
|Cash From Financing Activities||-1.57 B||Cash From Investing Activities||-526 M||Cash From Operating Activities||697 M||Gross Profit||3.18 B|
|Net Profit||-130 M||Operating Profit||45 M||Total Assets||31.95 B||Total Current Assets||13.06 B|
|Total Current Liabilities||7.44 B||Total Debt||7.37 B||Total Liabilities||16.83 B||Total Revenue||4.16 B|
|High 52 week||68.98||Low 52 week||45.12||Last close||50.65||Last change||-0.65%|
|RSI||48.82||Average true range||1.1||Beta||0.67||Volume||5.04 M|
|Simple moving average 20 days||0.81%||Simple moving average 50 days||1.69%||Simple moving average 200 days||-10.51%|
|Performance Week||-1.97%||Performance Month||3.33%||Performance Quart||-4.5%||Performance Half||-15.08%|
|Performance Year||-16.42%||Performance Year-to-date||-1.67%||Volatility daily||1.33%||Volatility weekly||2.98%|
|Volatility monthly||6.12%||Volatility yearly||21.18%||Relative Volume||180.93%||Average Volume||14.91 M|
|New High||New Low|
2019-03-24 13:00:52 | Is It Safe to Buy Biogen Stock Right Now?
2019-03-22 09:15:01 | Why Bristol-Myers Squibb BMY is a Great Dividend Stock Right Now
2019-03-21 10:10:02 | Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market
2019-03-21 10:03:02 | Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition
2019-03-20 17:45:09 | Bristol-Myers Squibb BMY Dips More Than Broader Markets: What You Should Know
2019-03-20 11:30:03 | Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study
2019-03-19 21:33:00 | Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle?
2019-03-19 15:17:06 | Analysts Have Revised BMY’s Target Price Downward in March
2019-03-19 14:17:00 | Starboard Is Against the Bristol-Myers and Celgene Deal. Now It Gets Interesting.
2019-03-19 13:14:00 | Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat
2019-03-19 11:56:03 | Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
2019-03-19 09:53:00 | Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers
2019-03-19 09:45:11 | Bristol-Myers Squibb and Starboard Value square off over Celgene deal
2019-03-19 08:40:12 | Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
2019-03-18 22:34:28 | U.S. FDA approves Roche's small cell lung cancer treatment
2019-03-18 18:44:10 | Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
2019-03-18 15:53:07 | Novartis' NVS Alcon Acquired PowerVision for $285 Million
2019-03-17 11:45:00 | AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
2019-03-15 14:00:00 | Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
2019-03-15 11:37:03 | Infinity Inks Deal With Roche for Phase II Study of IPI-549
2019-03-15 11:28:03 | Merck's Keytruda Gets EU Approval for Difficult Lung Cancer
2019-03-15 10:31:02 | Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
2019-03-15 09:46:07 | Some Bristol-Myers Squibb NYSE:BMY Shareholders Are Down 25%
2019-03-15 05:05:09 | J&J Seeks Approval for Darzalex in Expanded Patient Group
2019-03-14 09:32:49 | U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
2019-03-14 09:09:23 | U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid
2019-03-13 17:31:31 | 5 Biotech Stocks to Keep an Eye on in 2019
2019-03-13 16:37:00 | Celgene’s Positive Drug Data Bolsters Bristol-Myers Deal, Analyst Says
2019-03-13 12:27:00 | A Merck Cancer Treatment Has a Big Opportunity in China, Analyst Says
2019-03-12 10:24:41 | See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
2019-03-12 10:07:02 | Celgene CELG Submits Application for MS Drug in Europe
2019-03-12 10:01:02 | Pfizer's PFE Kidney Cancer Drug Combo Gets EMA's Validation
2019-03-12 06:06:00 | 3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade
2019-03-11 18:14:18 | Third Point holds Celgene stock, in bet Bristol-Myers deal will close -source
2019-03-11 13:41:00 | Here's Why Seres Therapeutics Stock Soared Today
2019-03-11 12:26:04 | Bayer Submits Application in EU for Prostate Cancer Drug
2019-03-11 11:06:03 | Is Bristol-Myers BMY a Solid Pick for Value Investors?
2019-03-08 11:04:04 | Celldex CLDX Q4 Loss Narrower than Expected, Sales Beat
2019-03-08 07:30:58 | How Novartis Is Transforming Its Structure in 2019
2019-03-08 00:49:59 | [$$] Why old-school asset managers are copying the activists
2019-03-07 17:22:00 | Bristol-Myers Squibb Announces Dividend
2019-03-07 11:58:00 | I Like the Long Side of Bristol-Myers Squibb
2019-03-07 10:31:14 | BMY and NVS: How Tax Rates and Interest Expenses Stack Up
2019-03-07 09:01:13 | How Novartis and BMY’s Dividend Profiles Stack Up
2019-03-07 07:32:14 | Novartis or BMY: Who’s Controlling Expenses Better?
2019-03-06 20:52:02 | Cramer Remix: This is something Bristol-Myers should do